Laboratory Testing for Transplantation Rejection - (0465) — MM 0465 | CIGNA Coverage Update

TL;DR: Cigna Healthcare modified MM 0465, its coverage policy for laboratory testing related to transplantation rejection, effective December 16, 2025. One code gets covered when criteria are met — CPT 81595 for heart transplant gene expression profiling — while eight other codes across heart, kidney, and liver transplant monitoring remain classified as experimental, investigational, or unproven.

This update to the Cigna transplantation rejection laboratory testing coverage policy draws a hard line between what Cigna will pay for and what it won't. If your team bills for any of the nine CPT codes under MM 0465 — including 0087U, 0088U, 0493U, 0540U, 0544U, 0575U, 0576U, 81558, and 81595 — you need to audit your charge capture before December 16, 2025.

Quick-Reference Table

Cigna Transplantation Rejection Laboratory Testing Coverage Criteria and Medical Necessity Requirements 2025

The core question under this coverage policy is simple: which blood tests for transplant rejection does Cigna consider medically necessary, and which does it consider experimental?

Right now, CPT 81595 is the only code in the MM 0465 Cigna system that clears the bar for coverage. CPT 81595 covers cardiology heart transplant mRNA gene expression profiling by real-time quantitative PCR of 20 genes. Cigna will reimburse this test when the applicable medical necessity criteria in the policy are met. That's a narrow window — one code, one organ, with specific criteria attached.

The medical necessity determination for transplant rejection billing hinges on whether the test in question has proven clinical utility. Cigna's position on CPT 81595 tells you the test has cleared that bar for heart transplants in the specific context where the criteria apply. The remaining eight codes have not.

If you're billing CPT 81595 for heart transplant monitoring, confirm your documentation supports every criterion in the policy before the effective date of December 16, 2025. Prior authorization requirements are common for high-cost molecular diagnostics under Cigna — verify whether prior auth applies to your specific plan contracts before submitting claims.

One thing worth flagging for your billing team: "medically necessary when criteria are met" isn't a rubber stamp. Cigna will scrutinize documentation on CPT 81595 claims. A claim denial on this code typically traces back to missing clinical documentation, not a billing error.

Cigna Transplantation Rejection Laboratory Testing Exclusions and Non-Covered Indications

Eight of the nine codes under MM 0465 carry the same designation: experimental, investigational, and unproven. That's a sweeping classification, and it covers tests across three organ types — heart, kidney, and liver.

For heart transplant monitoring, CPT 0087U — microarray gene expression profiling of 1,283 genes — is excluded. This is a more expansive panel than the covered CPT 81595, and Cigna's position is that the clinical evidence doesn't yet support it for reimbursement.

For kidney transplant monitoring, three codes are excluded. CPT 0088U covers microarray gene expression profiling of 1,494 genes for kidney allograft rejection. CPT 0493U and 0540U both address quantification of donor-derived cell-free DNA (cfDNA) using next-generation sequencing. CPT 0544U covers 48 variants by digital PCR using cell-free DNA from plasma for transplant monitoring. And CPT 81558 covers mRNA gene expression profiling by quantitative PCR for kidney allograft rejection.

For liver transplant monitoring, two codes are excluded: CPT 0575U for miRNA gene expression profiling by RT-PCR for liver allograft rejection, and CPT 0576U for quantitative donor-derived cell-free DNA for liver allograft rejection.

The real issue here is that cfDNA testing has gained significant traction in transplant medicine. Several of these codes — especially the cfDNA panels under 0493U, 0540U, 0544U, and 0576U — reflect technology that transplant programs are actively using. Cigna's position is that the evidence base for routine use isn't there yet. That may feel frustrating if your program relies on these tests, but for billing purposes the designation is clear: submit these codes to Cigna and expect denial.

Don't try to bill these as unlisted codes or recode them to covered alternatives. That creates compliance risk. If your physicians believe a denied test was medically necessary, route it through the appeals process with clinical literature support — not a rebill.

Coverage Indications at a Glance

Cigna Transplantation Rejection Laboratory Testing Billing Guidelines and Action Items 2025

Here's what your billing team needs to do before December 16, 2025.

One more thing: these codes show up in shared-savings and value-based contracts too. If your Cigna agreements include quality metrics or total cost of care arrangements, the exclusion of these tests may affect how your program's spend is calculated. Your contracting team should know about this update.

CPT, HCPCS, and ICD-10 Codes for Transplantation Rejection Laboratory Testing Under MM 0465

Covered CPT Codes (When Selection Criteria Are Met)

Not Covered / Experimental Codes

No ICD-10-CM codes are listed in MM 0465. Diagnosis code requirements are not specified in the policy data.